AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05500651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance and Movement Therapy (DMT)
Description: Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
Study NCT05089149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
Study NCT05089149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography
Description: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
Study NCT04828135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xenon gas
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
Study NCT05264168 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the reference group
Study NCT05518006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreMama Balance
Description: Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
Study NCT05518006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Blended Placebo drink
Study NCT05309044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planetary Health Diet Group
Description: This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
Study NCT05309044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet group
Description: This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
Study NCT05309044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waiting list group
Description: This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose.
Study NCT06393803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg KH607 tablets
Description: Subject receive KH607 tablets or placebo orally single dose.
Study NCT05264168 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Any apixaban dispensing claim is used as the exposure group
Study NCT05986266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
Study NCT06247046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live SK08 powder
Description: Oral Powder
Study NCT06247046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Powder
Study NCT05089149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
Study NCT05089149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
Study NCT04805216 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible.
Study NCT05089149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study NCT05099549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM24
Description: Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
Study NCT05986266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
Study NCT06264245 — intervention group
Intervention type: OTHER
Intervention: Audiological profile
Description: Video otoscopy Tympanometry High-frequency tonal audiometry
Study NCT06264245 — intervention group
Intervention type: OTHER
Intervention: Hearing self-assessments
Description: Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
Study NCT06264245 — intervention group
Intervention type: OTHER
Intervention: Objective and subjective audiological tests
Description: Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
Study NCT06264245 — intervention group
Intervention type: OTHER
Intervention: Self-assessment of exposure sound quality
Description: A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
Study NCT06352489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior component separation technique.
Description: By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
Study NCT05222503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Brace + OPUM Digital Knee
Description: Knee Brace + OPUM Digital Knee
Study NCT05222503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee Brace
Description: Knee Brace without OPUM Digital Knee
Study NCT05514106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meta-iodobenzylguanidine (MIBG) (123I)
Description: 1 administration of 123I-MIBG for a single SPECT scan
Study NCT05514106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 123I-MIBG scintigraphy
Description: SPECT scan involving 123I-MIBG as the ligand
Study NCT06044519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound
Study NCT04747522 — intervention group
Intervention type: DRUG
Intervention: SARS-CoV-2 vaccine
Description: SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
Study NCT04011748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: AA subjects will be recruited and followed by the treatment with SCE therapy.
Study NCT06307392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First intubation attempt with endotracheal tube plus bougie
Description: Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted.
Study NCT06307392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First intubation attempt with endotracheal tube alone
Description: During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted.
Study NCT05099549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex-vivo expanded autologous natural killer cells.
Study NCT06168383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 80mg
Description: once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
Study NCT06168383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 160mg
Description: once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
Study NCT06168383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral administration of placebo from Day 1 to Week 52.
Study NCT06322667 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT04718350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 6 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
Study NCT04718350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone at a dose of 50 mcg/kg
Description: milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
Study NCT06393777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: analgesic effect of honey
Study NCT05161312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iACT-BC: Oncovox
Description: A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
Study NCT06528015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics combined with enteric-coated budesonide capsule
Description: In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Study NCT06528015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: probiotics placebo combined with enteric-coated budesonide capsules
Description: In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Study NCT06393777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: honey
Description: analgesic effect of honey
Study NCT05443451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH
Description: The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
Study NCT05995925 — intervention group
Intervention type: OTHER
Intervention: Clinical Observation
Description: Clinical Observation
Study NCT06159569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LACRIACT
Description: LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit.
Study NCT03372070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cNEP
Description: soft silicon collar applied to anterior neck with negative pressure
Study NCT04600466 — intervention group
Intervention type: OTHER
Intervention: Molecular testing for all participants.
Description: Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
Study NCT05165992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Fentanyl
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
Study NCT05165992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Fentanyl
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
Study NCT04600466 — intervention group
Intervention type: OTHER
Intervention: Germline Testing
Description: Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
Study NCT04600466 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
Study NCT05726175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
Study NCT05726175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
Study NCT04677296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VS002A
Description: Amino acid based ORS/Medical food
Study NCT04677296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO-ORS
Description: WHO Oral rehydration solution, which is glucose based
Study NCT06444932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilization
Description: Patellofemoral and tibiofemoral joint mobilization
Study NCT06444932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Patellofemoral and tibiofemoral joint mobilization
Study NCT06444932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Lower limb resistance exercise training
Study NCT06444932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Description: Transcutaneous Electric Nerve Stimulation (TENS)
Study NCT06444932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Description: Transcutaneous Electric Nerve Stimulation (TENS)
Study NCT06444932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heating Pad
Description: Heating pad for heat therapy
Study NCT06444932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating Pad
Description: Heating pad for heat therapy
Study NCT05842421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography
Description: each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
Study NCT05695170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PreventT2 (Individual intervention)
Description: PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years.